Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.4256 | 1 | 1 |
Leishmania major | 0.4256 | 1 | 1 | |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.4256 | 1 | 1 |
Echinococcus granulosus | tm gpcr rhodopsin | 0.0645 | 0.1421 | 0.1421 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.0131 | 0.0201 | 0.0201 |
Echinococcus granulosus | voltage gated sodium channel Nav1 alpha subunit | 0.0724 | 0.161 | 0.161 |
Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.1583 | 0.3649 | 0.3649 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0047 | 0 | 0.5 |
Echinococcus multilocularis | calcium activated potassium channel | 0.0047 | 0.0001 | 0.0001 |
Echinococcus granulosus | sodium channel protein | 0.0724 | 0.161 | 0.161 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.4256 | 1 | 1 |
Toxoplasma gondii | sedoheptulose-1,7-bisphosphatase | 0.1583 | 0.3649 | 0.3649 |
Echinococcus granulosus | proto oncogene serine:threonine protein kinase | 0.0131 | 0.0201 | 0.0201 |
Echinococcus multilocularis | tm gpcr rhodopsin gpcr rhodopsin superfamily | 0.0645 | 0.1421 | 0.1421 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0131 | 0.0201 | 0.0201 |
Leishmania major | calcium channel protein, putative,ion transporter, putative | 0.0724 | 0.161 | 0.161 |
Echinococcus granulosus | calcium activated potassium channel | 0.0047 | 0.0001 | 0.0001 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0047 | 0 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.4256 | 1 | 1 |
Echinococcus multilocularis | sodium channel protein | 0.0724 | 0.161 | 0.161 |
Toxoplasma gondii | fructose-bisphospatase I | 0.1583 | 0.3649 | 0.3649 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.4256 | 1 | 1 |
Toxoplasma gondii | fructose-bisphospatase II | 0.4256 | 1 | 1 |
Trypanosoma brucei | sedoheptulose-1,7-bisphosphatase | 0.1583 | 0.3649 | 0.3649 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.4256 | 1 | 1 |
Onchocerca volvulus | Serine\/threonine protein kinase homolog | 0.0131 | 0.0201 | 1 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.0131 | 0.0201 | 0.0201 |
Brugia malayi | Protein kinase domain containing protein | 0.0131 | 0.0201 | 0.0201 |
Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.1583 | 0.3649 | 0.3649 |
Brugia malayi | Serine/threonine-protein kinase Pim-3 | 0.0131 | 0.0201 | 0.0201 |
Echinococcus multilocularis | proto oncogene serine:threonine protein kinase | 0.0131 | 0.0201 | 0.0201 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.4256 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AD50 (functional) | = 0.9 uM kg-1 | Antinociceptive activity of the compound after subcutaneous administration in mice. p<0.05 vs dermorphin | ChEMBL. | 9986710 |
IC50 (functional) | = 2.1 nM | In vitro concentration of the compound required to inhibit electrically evoked twitch in isolated guinea pig ileum. | ChEMBL. | 9986710 |
IC50 (functional) | = 35 nM | In vitro concentration of the compound required to inhibit electrically evoked twitch in isolated mouse vas deferens. | ChEMBL. | 9986710 |
Ki (binding) | = 0.5 nM | Displacement of [3H]-DAGO from Opioid receptor mu 1 of adult male mouse brain. | ChEMBL. | 9986710 |
Ki (binding) | = 1411 nM | Displacement of [3H]-NLT from Opioid receptor delta 1 of adult male mouse brain. | ChEMBL. | 9986710 |
T1/2 (ADMET) | = 20 min | Half-life time of enzymatic breakdown of the compound in mouse liver. | ChEMBL. | 9986710 |
T1/2 (ADMET) | = 30 min | Half-life time of enzymatic breakdown of the compound in mouse brain. | ChEMBL. | 9986710 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.